Influenza vaccines provide diminished protection but are cost-saving in older adults

Journal of Internal Medicine

Volumn 267, Issue 2, 2010, Pages 220-227

  Deans, G D ^a   Stiver, H G ^a   McElhaney, J E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Influenza; Older adults; Vaccine

Indexed keywords

INFLUENZA VACCINE;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; CELLULAR IMMUNITY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HEADACHE; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INJECTION SITE REACTION; NOSE CONGESTION; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION; VACCINES, VIROSOME;

EID: 74849106752     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2009.02201.x     Document Type: Review

References (45)

1. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 2004 292 : 1333 1340.
2. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003 289 : 179 186. (Pubitemid 36068705)
3. Hak E, Wei F, Nordin J, Mullooly J, Poblete S, Nichol KL. Development and validation of a clinical prediction rule for hospitalization due to pneumonia or influenza or death during influenza epidemics among community-dwelling elderly persons. J Infect Dis 2004 189 : 450 458.
4. Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, Miller MA. Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol 2004 160 : 492 502.
5. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. N Engl J Med 1983 309 : 13 7.
6. Rimmelzwaan GF, McElhaney JE. Correlates of protection: novel generations of influenza vaccines. Vaccine 2008 26 (Suppl. 4 D41 4.
7. Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009 58 : 1 52.
8. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994 272 : 1661 1665. (Pubitemid 24359136)
9. Rivetti D, Jefferson T, Thomas R et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2006 3 : CD004876.
10. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2002 20 : 1831 1836.
11. Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007 7 : 658 666.
12. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 2007 357 : 1373 1381.
13. Nichol KL. Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy. Vaccine 2009 27 : 6305 6311.
14. Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007 25 : 6852 6862.
15. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000 61 : 94 9.
16. Legrand J, Vergu E, Flahault A. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 2006 24 : 6605 6611.
17. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, Stevenson PG. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997 159 : 105 117.
18. Hsu HC, Scott DK, Mountz JD. Impaired apoptosis and immune senescence - cause or effect? Immunol Rev 2005 205 : 130 146.
19. McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006 176 : 6333 6339.
20. Mullooly JP, Bennett MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994 121 : 947 952.
21. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994 331 : 778 784.
22. McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take? J Infect Dis 2008 198 : 632 634.
23. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007 25 : 659 663.
24. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004 351 : 2286 2294.
25. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008 198 : 650 658.
26. Harper SA, Fukuda K, Cox NJ, Bridges CB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003 52 : 1 8.
27. Stepanova L, Naykhin A, Kolmskog C et al. The humoral response to live and inactivated influenza vaccines administered alone and in combination to young adults and elderly. J Clin Virol 2002 24 : 193 201.
28. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998 338 : 1405 1412.
29. Belshe RB, Edwards KM, Vesikari T et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007 356 : 685 696.
30. Monto AS, Ohmit SE, Petrie JG et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009 361 : 1260 1267.
31. Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann Intern Med 1992 117 : 625 633.
32. Gorse GJ, O'Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine 2003 21 : 2133 2144.
33. Gorse GJ, O'Connor TZ, Newman FK et al. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 2004 190 : 11 9. Epub 2004 May 26.
34. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001 19 : 2673 2680.
35. Squarcione S, Sgricia S, Biasio LR, Perinetti E. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects. Vaccine 2003 21 : 1268 1274.
36. Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect 2005 133 : 687 693.
37. Huckriede A, Bungener L, Stegmann T et al. The virosome concept for influenza vaccines. Vaccine 2005 23 (Suppl. 1 S26 38.
38. de Bruijn IA, Nauta J, Cramer WC, Gerez L, Palache AM. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2005 23 (Suppl. 1 S39 49.
39. de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007 26 : 119 127.
40. Langley JM, Halperin SA, McNeil S et al. Safety and immunogenicity of a proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 2006 24 : 1601 1608.
41. Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006 166 : 1121 1127.
42. de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RG, Knook DL. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999 179 : 31 6.
43. Co MD, Orphin L, Cruz J et al. Discordance between antibody and T cell responses in recipients of trivalent inactivated influenza vaccine. Vaccine 2008 26 : 1990 1998.
44. Jain S, Kamimoto L, Bramley AM et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009 361 : 1935 1944.
45. Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009 361 : 1945 1952.